Polyneuropathie bei Morbus Fabry

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Univ.-Prof. Dr. Stefan Quasthoff

Allgemeine Neurologie,Universitätsklinik für Neurologie, Medizinische Universität Graz


Literatur
1 Ries M et al., Pediatric Fabry disease. Pediatrics 2005; 115(3):e344–55
2 Ries M et al., The early clinical phenotype of Fabry disease: a study on 35 European children and adoles­cents. Eur J Pediatr 2003; 162(11):767–72
3 Mehta A et al., Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34(3):236–42
4 Whybra C et al., Clinical manifestation in female Fabry disease patients. Contrib Nephrol 2001; 136:245– 50
5 MacDermot J et al., Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001; 429(1–3):121–5
6 Dutsch M et al., Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002; 19(6):575–86
7 Luciano CA et al., Physiologic characterization of neuropathy in Fabry disease. Muscle Nerve 2002; 26(5):622–29
8 Dyck PJ et al., A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold. Neurology 1993; 43(8):1508–12
9 Scott LJ et al., Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999; 52(6):1249–54
10 Hilz MJ et al., Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 2000; 84(2–3):361–5
11 Gadoth N et al., Involvement of dorsal root ganglia in Fabry’s disease. J Med Genet 1983; 20(4):309–12
12 Kocen RS et al., Peripheral nerve involvement in Fabry’s disease. Arch Neurol 1970; 22(1):81–8
13 Bischoff a et al., Peripheral neurological disorders in Fabry’s disease (angiokeratoma corporis diffusum universale). Clinical and electron microscopic findings in a case. Klin Wochenschr 1968; 46(12):666–71
14 Gemignani F et al., Pathological study of the sural nerve in Fabry’s disease. Eur Neurol 1984; 23(3):173–81
15 Sima AA et al., Involvement of peripheral nerve and muscle in Fabry’s disease. Histologic, ultrastructural, and morphometric studies. Arch Neurol 1978; 35(5):291–301
16 Hozumi I et al., Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry’s disease. J Neurol Sci 1989; 90(3):273–80
17 Onishi A et al., Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol 1974; 31(2):120–7
18 Cable WJ et al., Fabry disease: impaired autonomic function. Neurology 1982; 32(5):498–502
19 Altarescu GM et al., Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001; 60(1):46–51
20 Kato H et al., Fabry’s disease. Intern Med 1992; 31(5):682–5
21 Kang WH et al., Generalized anhidrosis associated with Fabry’s disease. J Am Acad Dermatol 1987; 17(5 Pt 2):883–7
22 Fealey RD et al., Thermoregulatory sweat test. In: Low PA (ed.), Clinical autonomic disorders. 2nd ed. Philadelphia: Lippincott-Raven 1997; 245–57
23 Low PA et al., The autonomic laboratory. Am J Electroneurodiagn Technol 1999; 39(2):65–76
24 Schiffmann R et al., Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003; 28:703– 10
25 Cable WJ et al., Fabry disease: significance of ultra-structural localization of lipid inclusions in dermal nerves. Neurology 1982; 32(4):347–53
26 Schiffmann R et al., Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl 2002; 91(439):48–52
27 Fukuhara N et al., Fabry’s disease on the mechanism of the peripheral nerve involvement. Acta Neuropathol.(Berl.) 1975; 33(1):9–21
28 Yamamoto K et al., Possible mechanism of anhidrosis in a symptomatic female carrier of Fabry’s disease: an assessment by skin sympathetic nerve activity and sympathetic skin response. Clin Auton Res 1996; 6(2):107–10
29 Lao LM et al., The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 1998; 18(2):109–17
30 Thomas PK, The anatomical substratum of pain evidence derived from morphometric studies on peripheral nerve. Can J Neurol Sci 1974; 1(2):92–7
31 Inagaki M et al., Relative hypoxia of the extremities in Fabry disease. Brain Dev 1992; 14(5):328–33
32 Stemper B, Hilz MJ, Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol 2003; 250(8):970–6
33 Altarescu G et al., Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001; 32(7):1559–62
34 Lien YH et al., Unexpected diagnosis of fabry disease in an 80-year-old man with syncope. Cardiology 2001; 96(2):115–6
35 Menkes DL et al., Fabry’s disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis. Mil Med 1997; 162(11):773–6
36 Mutoh T et al., Severe orthostatic hypotension in a female carrier of Fabry’s disease. Arch Neurol 1988; 45(4):468– 72
37 Seino Y et al., Peripheral hemodynamics in patients with Fabry’s disease. Am Heart J 1983; 105(5):783–7
38 Hilz MJ et al., Enzyme replacement therapy improves function of C-, A-delta-, and A-beta-nerve fibers in Fabry neuropathy. Neurology 2004; 62(7):1066– 72
39 Attal N et al., Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl 1999; 173:12–24
40 Zimmermann M, Pathobiology of neuropathic pain. Eur J Pharmacol 2001; 429(1–3):23–37
41 Backonja MM, Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16(2 Suppl):S67–72
42 Coward K et al., Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain 2000; 85(1–2):41–50
43 Dougherty JA et al., Gabapentin: a unique anti-epileptic agent. Neurol Res 2001; 23(8):821–9
44 Filling-Katz MR et al., Carbamazepine in Fabry’s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 1989; 39(4):598–600
45 Schiffmann R et al., Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 2001; 285(21):2743–9

neuro 04|2014

Herausgeber: Österreichische Gesellschaft für Neurologie, Univ.-Prof. Dr. Reinhold Schmidt, Präsident der ÖGN
Publikationsdatum: 2014-12-18